Gilead

Shop Support DM Logo

Investigations

Scorpio Our burning planet amabhungane Declassified UK

News & Analysis

Business Maverick Maverick Citizen Sport Newsdeck Maverick News Nelson Mandela Bay Johannesburg

Features

Opinionistas Maverick Life TGIFood Blog Podcasts Webinars Zapiro Cartoons Op-eds

Newspaper

E-edition Subscribe Delivery Queries

DM is much better if you are signed in...

Enter your email below and we will send you a mail with a link or one-time pin to login

Sign in with password
Sign in with OAuth

Get Support DM Shop Support DM

Gilead

How South Africa can help secure immediate, global access to HIV prevention drug lenacapavir

Op-eds

How South Africa can help secure immediate, global access to HIV prevention drug lenacapavir

by: Tian Johnson, Fatima Hassan, Asia Russell and Sangeeta Shashikant

Talks have started to get the twice-yearly anti-HIV jab registered in SA

Maverick Citizen

Talks have started to get the twice-yearly anti-HIV jab registered in SA

by: Mia Malan

Lenacapavir — what it would it take to get the six-monthly anti-HIV jab to South Africa

Maverick Citizen

Lenacapavir — what it would it take to get the six-monthly anti-HIV jab to South Africa

by: Mia Malan and Linda Pretorius

Gilead questions WHO study that cast doubts on drug's COVID-19 benefits

World, Newsdeck, COVID-19

Gilead questions WHO study that cast doubts on drug's COVID-19 benefits

by: Reuters

A redeeming moment for the SA government: A case for compulsory licensing in the age of Covid-19

South Africa

A redeeming moment for the SA government: A case for compulsory licensing in the age of Covid-19

by: Fatima Hassan

Return to Gilead – even more gripping this time around

Maverick Life

Return to Gilead – even more gripping this time around

by: Ed Stoddard

Debug: hasMoreArticles=false, articles.length=6